Skip to main content
Top
Published in: Comparative Clinical Pathology 6/2012

01-12-2012 | Original Article

Impact of proliferative indices and tumor suppressor genes on treatment response in marginal zone lymphomas

Authors: Mohammad Hussaini, Friederike Kreisel, Anjum Hassan

Published in: Comparative Clinical Pathology | Issue 6/2012

Login to get access

Abstract

Firstly, increased Ki67 and MUM-1 staining has been associated with worse prognosis in marginal zone B cell lymphomas (MZL). However, ours is the first study to assess the impact of proliferative indices on chemotherapy response. Secondly, loss of p53 and p16 tumor suppressor genes (TSG) has traditionally been associated with cancer progression. The significance of these markers in MZL was investigated. Thirdly, we explored the role of proliferative indices and tumor suppressor genes in identifying MZLs with significant plasmacytic differentiation (PD). Consecutive MZL cases (2006–2008) were identified. Slides were reviewed to confirm the diagnosis; immunohistochemical stains for Ki67, MUM-1, WT-1, p53, and p16 were subsequently performed and graded for percentage staining. Wilcoxon two-sample test and Pearson correlation coefficient were performed. Twenty-nine cases were analyzed. None of the assayed markers were correlated with treatment response. Ki67 and MUM1 expression, however, were correlated with PD (p = 0.0136 and p = 0.0042). A correlation between MUM1 and p16 staining was also seen (p = 0.0006). IHC assay for TSGs, p53 and p16, and proliferative indices (Ki67, MUM1, WT1) is unlikely to predict treatment response in low-grade MZL. Ki67 and MUM1 staining, however, may serve as a useful adjunct in ascribing PD.
Literature
go back to reference Aleman BM, Haas RL, van der Maazen RW (2010) Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 24(1):27–34PubMedCrossRef Aleman BM, Haas RL, van der Maazen RW (2010) Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 24(1):27–34PubMedCrossRef
go back to reference Baldini L, Guffanti A, Cro L, Fracchiolla NS, Colombi M, Motta M et al (1997) Poor prognosis in non-villous splenic marginal zone cell lymphoma is associated with p53 mutations. Br J Haematol 99(2):375–378PubMedCrossRef Baldini L, Guffanti A, Cro L, Fracchiolla NS, Colombi M, Motta M et al (1997) Poor prognosis in non-villous splenic marginal zone cell lymphoma is associated with p53 mutations. Br J Haematol 99(2):375–378PubMedCrossRef
go back to reference Bennett M, Schechter GP (2010) Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. Semin Hematol 47(2):143–147PubMedCrossRef Bennett M, Schechter GP (2010) Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. Semin Hematol 47(2):143–147PubMedCrossRef
go back to reference Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA et al (2000) Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 95(6):1950–1956PubMed Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA et al (2000) Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 95(6):1950–1956PubMed
go back to reference Brown JR, Friedberg JW, Feng Y, Scofield S, Phillips K, Dal Cin P et al (2009) A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol 146(6):685–686CrossRef Brown JR, Friedberg JW, Feng Y, Scofield S, Phillips K, Dal Cin P et al (2009) A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol 146(6):685–686CrossRef
go back to reference Bryant RJ, Banks PM, O'Malley DP (2006) Ki67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders. Histopathology 48(5):505–515PubMedCrossRef Bryant RJ, Banks PM, O'Malley DP (2006) Ki67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders. Histopathology 48(5):505–515PubMedCrossRef
go back to reference Camacho FI, Mollejo M, Mateo MS, Algara P, Navas C, Hernández JM et al (2001) Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol 25(10):1268–1276PubMedCrossRef Camacho FI, Mollejo M, Mateo MS, Algara P, Navas C, Hernández JM et al (2001) Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol 25(10):1268–1276PubMedCrossRef
go back to reference Chacón JI, Mollejo M, Muñoz E, Algara P, Mateo M, Lopez L et al (2002) Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 100(5):1648–1654PubMed Chacón JI, Mollejo M, Muñoz E, Algara P, Mateo M, Lopez L et al (2002) Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 100(5):1648–1654PubMed
go back to reference Du MQ, Isaccson PG (2002) Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 3(2):97–104PubMedCrossRef Du MQ, Isaccson PG (2002) Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 3(2):97–104PubMedCrossRef
go back to reference Du M, Singh N, Husseuin A, Isaacson PG, Pan L et al (1996) Positive correlation between apoptotic and proliferative indices in gastrointestinal lymphomas of mucosa-associated lymphoid tissue (MALT). J Pathol 178(4):379–384PubMedCrossRef Du M, Singh N, Husseuin A, Isaacson PG, Pan L et al (1996) Positive correlation between apoptotic and proliferative indices in gastrointestinal lymphomas of mucosa-associated lymphoid tissue (MALT). J Pathol 178(4):379–384PubMedCrossRef
go back to reference Federico M, Molica S, Bellei M, Luminari S (2009) Prognostic factors in low-grade non-Hodgkin lymphomas. Curr Hematol Malig Rep 4:202–210PubMedCrossRef Federico M, Molica S, Bellei M, Luminari S (2009) Prognostic factors in low-grade non-Hodgkin lymphomas. Curr Hematol Malig Rep 4:202–210PubMedCrossRef
go back to reference Franco R, Camacho FI, Caleo A, Staibano S, Bifano D, De Renzo A et al (2006) Nuclear bcl10 expression characterizes a group of ocular adnexa MALT lymphomas with shorter failure-free survival. Mod Pathol 19(8):1055–1067PubMed Franco R, Camacho FI, Caleo A, Staibano S, Bifano D, De Renzo A et al (2006) Nuclear bcl10 expression characterizes a group of ocular adnexa MALT lymphomas with shorter failure-free survival. Mod Pathol 19(8):1055–1067PubMed
go back to reference Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D (2001) p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood 97(11):3552–3558PubMedCrossRef Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D (2001) p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood 97(11):3552–3558PubMedCrossRef
go back to reference Hunter T, Pines J (1994) Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79:573–582PubMedCrossRef Hunter T, Pines J (1994) Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79:573–582PubMedCrossRef
go back to reference Imamura J, Miyashi I, Koeffler PH (1994) P53 in haematologic malignancies. Blood 84:2412–2421PubMed Imamura J, Miyashi I, Koeffler PH (1994) P53 in haematologic malignancies. Blood 84:2412–2421PubMed
go back to reference Insabato L, Di Vizio D, Tornillo L, D'Armiento FP, Siciliano A, Milo M et al (2003) Clinicopathologic and immunohistochemical study of surgically treated primary gastric MALT lymphoma. J Surg Oncol 83(2):106–111PubMedCrossRef Insabato L, Di Vizio D, Tornillo L, D'Armiento FP, Siciliano A, Milo M et al (2003) Clinicopathologic and immunohistochemical study of surgically treated primary gastric MALT lymphoma. J Surg Oncol 83(2):106–111PubMedCrossRef
go back to reference Kato H, Miyazaki T, Fukai Y, Nakajima M, Sohda M, Takita J et al (2003) A new proliferation marker, minichromosome maintenance protein 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma. J Surg Oncol 84(1):24–30PubMedCrossRef Kato H, Miyazaki T, Fukai Y, Nakajima M, Sohda M, Takita J et al (2003) A new proliferation marker, minichromosome maintenance protein 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma. J Surg Oncol 84(1):24–30PubMedCrossRef
go back to reference Kovalevska LM, Yurchenko OV, Shlapatska LM, Berdova GG, Mikhalap SV, Van Lint J et al (2006) Immunohistochemical studies of protein kinase D (PKD) 2 expression in malignant human lymphomas. Exp Oncol 28(3):225–230PubMed Kovalevska LM, Yurchenko OV, Shlapatska LM, Berdova GG, Mikhalap SV, Van Lint J et al (2006) Immunohistochemical studies of protein kinase D (PKD) 2 expression in malignant human lymphomas. Exp Oncol 28(3):225–230PubMed
go back to reference Li HL, Sun BZ, Ma FC (2004) Expression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 10(13):1862–1866PubMed Li HL, Sun BZ, Ma FC (2004) Expression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 10(13):1862–1866PubMed
go back to reference Liggett WH, Sidransky D (1998) Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16(3):1197–1206PubMed Liggett WH, Sidransky D (1998) Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16(3):1197–1206PubMed
go back to reference Menssen HD, Renkl HJ, Rodeck U, Kari C, Schwartz S, Thiel E (1997) Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia. Int J Cancer 70(5):518–523PubMedCrossRef Menssen HD, Renkl HJ, Rodeck U, Kari C, Schwartz S, Thiel E (1997) Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia. Int J Cancer 70(5):518–523PubMedCrossRef
go back to reference Olszewski M, Huang W, Chou PM, Duerst R, Kletzel M (2005) Wilms' tumor 1 (WT1) gene in hematopoiesis: a surrogate marker of cell proliferation as a possible mechanism of action? Cytotherapy 7(1):57–61PubMedCrossRef Olszewski M, Huang W, Chou PM, Duerst R, Kletzel M (2005) Wilms' tumor 1 (WT1) gene in hematopoiesis: a surrogate marker of cell proliferation as a possible mechanism of action? Cytotherapy 7(1):57–61PubMedCrossRef
go back to reference Paterlini P, Suberville AM, Zindy F, Melle J, Sonnier M, Marie JP et al (1993) Cyclin A expression in human hematological malignancies: a new marker of cell proliferation. Cancer Res 53(2):235–238PubMed Paterlini P, Suberville AM, Zindy F, Melle J, Sonnier M, Marie JP et al (1993) Cyclin A expression in human hematological malignancies: a new marker of cell proliferation. Cancer Res 53(2):235–238PubMed
go back to reference Petit B, Chaury MP, Le Clorennec C, Jaccard A, Gachard N, Moalic-Judge S et al (2005) Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup. Haematologica 90(2):200–206PubMed Petit B, Chaury MP, Le Clorennec C, Jaccard A, Gachard N, Moalic-Judge S et al (2005) Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup. Haematologica 90(2):200–206PubMed
go back to reference Raderer M, Paul de Boer J (2004) Role of chemotherapy in gastric MALT lymphoma, diffuse large B-cell lymphoma and other lymphomas. Best Pract Res Clin Gastroenterol 24(1):19–26CrossRef Raderer M, Paul de Boer J (2004) Role of chemotherapy in gastric MALT lymphoma, diffuse large B-cell lymphoma and other lymphomas. Best Pract Res Clin Gastroenterol 24(1):19–26CrossRef
go back to reference Rose DS, Maddox PH, Brown DC (1994) Which proliferation markers for routine immunohistology? A comparison of five antibodies. J Clin Pathol 47:1010–1014PubMedCrossRef Rose DS, Maddox PH, Brown DC (1994) Which proliferation markers for routine immunohistology? A comparison of five antibodies. J Clin Pathol 47:1010–1014PubMedCrossRef
go back to reference Ruiz-Ballesteros E, Mollejo M, Rodriguez A, Camacho FI, Algara P, Martinez N et al (2005) Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 106(5):1831–1838PubMedCrossRef Ruiz-Ballesteros E, Mollejo M, Rodriguez A, Camacho FI, Algara P, Martinez N et al (2005) Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 106(5):1831–1838PubMedCrossRef
go back to reference Schrader C, Meusers P, Brittinger G, Teymoortash A, Siebmann JU, Janssen D et al (2004) Topoisomerase II expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia 18:1200–1206PubMedCrossRef Schrader C, Meusers P, Brittinger G, Teymoortash A, Siebmann JU, Janssen D et al (2004) Topoisomerase II expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia 18:1200–1206PubMedCrossRef
go back to reference Sharpless NE, Alson S, Chan S, Silver DP, Castrillon DH, DePinho RA (2002) p16(INK4a) and p53 deficiency cooperate in tumorigenesis. Cancer Res 62(10):2761–2765PubMed Sharpless NE, Alson S, Chan S, Silver DP, Castrillon DH, DePinho RA (2002) p16(INK4a) and p53 deficiency cooperate in tumorigenesis. Cancer Res 62(10):2761–2765PubMed
go back to reference Smith-Ravin J, Spencer J, Beverley PC, Isaacson PG (1990) Characterization of two monoclonal antibodies (UCL4D12 and UCL3D3) that discriminate between human mantle zone and marginal zone B cells. Clin Exp Immunol 82:181–187PubMedCrossRef Smith-Ravin J, Spencer J, Beverley PC, Isaacson PG (1990) Characterization of two monoclonal antibodies (UCL4D12 and UCL3D3) that discriminate between human mantle zone and marginal zone B cells. Clin Exp Immunol 82:181–187PubMedCrossRef
go back to reference Spencer J, Perry ME, Dunn-Walters D (1998) Human marginal-zone B cells. Immunol Today 19(9):421–426PubMedCrossRef Spencer J, Perry ME, Dunn-Walters D (1998) Human marginal-zone B cells. Immunol Today 19(9):421–426PubMedCrossRef
go back to reference Stefanaki K, Tzardi M, Kouvidou C, Chaniotis V, Bolioti M, Vlychou M et al (1998) Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue. Anticancer Res 18(4A):2403–2408PubMed Stefanaki K, Tzardi M, Kouvidou C, Chaniotis V, Bolioti M, Vlychou M et al (1998) Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue. Anticancer Res 18(4A):2403–2408PubMed
go back to reference Sundram U, Harvell JD, Rouse RV, Natkunam Y (2003) Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Mod Pathol 16(8):802–810PubMedCrossRef Sundram U, Harvell JD, Rouse RV, Natkunam Y (2003) Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Mod Pathol 16(8):802–810PubMedCrossRef
go back to reference Suzuki H, Saito Y, Hibi T (2009) Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) lymphoma: updated review of clinical outcomes and the molecular pathogenesis. Gut Liver 3(2):81–87PubMedCrossRef Suzuki H, Saito Y, Hibi T (2009) Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) lymphoma: updated review of clinical outcomes and the molecular pathogenesis. Gut Liver 3(2):81–87PubMedCrossRef
go back to reference Swanson S, Brooks J (1990) Proliferation markers Ki-67 and p105 in soft-tissue lesions. Correlation with DNA flow cytometric characteristics. Am J Pathol 137(6):1491–1500PubMed Swanson S, Brooks J (1990) Proliferation markers Ki-67 and p105 in soft-tissue lesions. Correlation with DNA flow cytometric characteristics. Am J Pathol 137(6):1491–1500PubMed
go back to reference Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (2008) WHO classification of tumors and haematopoeitic and lymphoid tissues. IARC, Lyon Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (2008) WHO classification of tumors and haematopoeitic and lymphoid tissues. IARC, Lyon
go back to reference Timár J, Mészáros L, Orosz Z, Albini A, Rásó E (2005) WT1 expression in angiogenic tumours of the skin. Histopathology 47:67–73PubMedCrossRef Timár J, Mészáros L, Orosz Z, Albini A, Rásó E (2005) WT1 expression in angiogenic tumours of the skin. Histopathology 47:67–73PubMedCrossRef
go back to reference Wohlschlegel JA, Kutok JL, Weng AP, Dutta A (2002) Expression of geminin as a marker of cell proliferation in normal tissues and malignancies. Am J Pathol 161(1):267–273PubMedCrossRef Wohlschlegel JA, Kutok JL, Weng AP, Dutta A (2002) Expression of geminin as a marker of cell proliferation in normal tissues and malignancies. Am J Pathol 161(1):267–273PubMedCrossRef
go back to reference Wołowiec D, Deviller P, Simonin D, Souchier C, Rimokh R, Benchaib M et al (1995) Cdk1 is a marker of proliferation in human lymphoid cells. Int J Cancer 61(3):381–388PubMedCrossRef Wołowiec D, Deviller P, Simonin D, Souchier C, Rimokh R, Benchaib M et al (1995) Cdk1 is a marker of proliferation in human lymphoid cells. Int J Cancer 61(3):381–388PubMedCrossRef
go back to reference Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H et al (2005) Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 23:8018–8024PubMedCrossRef Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H et al (2005) Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 23:8018–8024PubMedCrossRef
Metadata
Title
Impact of proliferative indices and tumor suppressor genes on treatment response in marginal zone lymphomas
Authors
Mohammad Hussaini
Friederike Kreisel
Anjum Hassan
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Comparative Clinical Pathology / Issue 6/2012
Print ISSN: 1618-5641
Electronic ISSN: 1618-565X
DOI
https://doi.org/10.1007/s00580-011-1271-y

Other articles of this Issue 6/2012

Comparative Clinical Pathology 6/2012 Go to the issue